21 August, 2018- Expanded BioTaiwan 2018 program a roaring success
21 August, 2018 The 16th annual BioTaiwan festival of events has concluded, and by all measures was a resounding success. With new conferences on offer, an expanded company presentation program, and fresh new display areas showcasing technology transfer and innovation, BioTaiwan—held at East Taipei's CTBC Financial Park and the nearby Nangang Exhibition Center—goes from strength to strength, year by year, reflecting the spectacular growth of the biomedical sector both in Taiwan and in the whole Asia-Pacific region. Highlights were many: The main conferences, including BioBusiness Asia, the Greater China Opportunities Conference and the inaugural Southeast Asia Opportunities Conference, attracted more than 1,200 attendees. One-on-one partnering was also a popular feature of this year's festival, with more than 500 meetings held. An accompanying program of biomedical seminars and workshops was also heavily attended. And the four-day exhibition, expanded this year over an extra floor of the exhibition hall, showcased over 600 companies' products and technologies, drew in nearly 100,000 visitors. Reflecting the importance of the biomedical sector to Taiwan's future development plans, BioTaiwan 2018 was opened by Taiwan President Tsai Ing-wen. In her address, Tsai reiterated the government's strong support for the continuing development of the biotechnology and pharmaceutical industries, and offered up her best wishes for a successful gathering. The Taiwan government indeed has high expectations for this industry, and has set ambitious development goals including fostering 20 new drugs and 80 high-value medical devices in global markets, creating 10 flagship brands in health services by 2025, and generating revenues in excess of NT$1 trillion (US$33 billion). Kicking off BioTaiwan 2018 was its signature event, the BioBusiness Asia Conference, expanded this year to three days from the usual two. 1,200 attended the conference from 400 companies from Asia and beyond including Japan, China, Singapore, South Korea, Hong Kong and the United States, 20 countries in total. Topics covered over three days of presentations included precision medicine, cell and gene therapy, diagnostics and devices, topics around the rapidly growing digital health domain, global industry trends, investment strategies, new business models, and biologics and biosimilars manufacturing and development issues. The four-day BioTaiwan Exhibition took on a new look this year, expanding over an additional floor of the Nangang Exhibition Hall, featuring not only the latest biotechnology and medtech innovations but also health and beauty products. This year a special zones was set up on the exhibition floor; the Technology Transfer Zone, hosting universities and research institutes with transfer-ready technologies. This zone included presenting space, meeting areas, and convenient one-on-one partnering booths. Another interesting and popular addition to the exhibition this year was 'Radio BioTaiwan', an onsite interview and recording booth where selected conference speakers took the time to sit down for 'fireside chat' discussions on bioindustry-related topics with Taiwan Bio-Industry Organization (TBIO) staff, for later broadcast. A recurring feature of BioTaiwan is the presentation of the annual Taiwan BIO Awards, organized by TBIO. This year, in the category of Outstanding Company of the Year, CH Biotech R&D and TaiGen Biotechnology shared the honors. In the category Emerging Company of the Year, Foresee Pharmaceuticals and Wiltrom came up winners. And in Innovation of the Year three technologies were recognized; Eveline Ovulation Test System, from Ixensor; Anticancer New Drug B05/EndoTAG®-1, from SynCore Biotechnology; and TAH4411 ODF－A Patient Friendly Formula for Prevention of Nausea and Vomiting, from TAHO Pharmaceuticals. This year the Company Presentations program witnessed a record 43 companies taking turns over three days to make their pitch to gatherings of interested investors, partners and collaborators. As well as a strong local showing from biotech, pharmaceutical, medical devices and materials companies, nearly half of the presenting firms this year were from abroad; Europe, the United States, Japan, South Korea, and Southeast Asia, with big names including Merck, GE Healthcare and first-time participants Samsung Biologics. Japan had a particularly strong showing at BioTaiwan 2018, with five firms joining the Company Presentations program including Otsuka Holdings, Sumitomo Dainippon Pharma, CAR-T cell therapy company Noile-Immune, and Daiwa Enterprise Investment. And Japan sent a large contingency to further participate in BioTaiwan 2018 conferences, including immune-regulation therapy firm Regimmune, biopharmaceutical manufacturing viral clearance test company ViSpot, Kobe University, and FunPep, a company developing functional peptides. The ever-popular Greater China Opportunities Conference again featured speakers and interest from both sides of the Taiwan Strait, but this year was joined by an all-new event, the Southeast Asian Opportunities Conference. With the Taiwan government encouraging business engagement with Southeast Asia under its New Go South Policy, this inaugural one-day gathering took advantage of renewed interest in the region with presentations from Southeast Asian investment, business and biotech experts. Johnsee Lee, chairman of the BioTaiwan Organizing Committee as well as chairman of the Taiwan Bio Industry Organization, remarked in the opening session of BioBusiness Asia the growing standing of BioTaiwan in Asia and beyond. "BioTaiwan has become an important vehicle to help connect Taiwan with the global biotech community and to let the world see Taiwan. It's also an increasingly important platform for international business exchange," he said. About Taiwan Bio Industry Organization: Taiwan Bio Industry Organization (TBIO), established in 1989, is the largest and the most influential biotechnology organization in Taiwan. TBIO represents over 300 members ranging from private companies and academic institutes to government bodies involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology. Our mission is to provide advocacy, business development, global partnering opportunity and communication service for our members, and to foster the development of biotech industry in Taiwan.